Articles by William Soliman

  1. AI Agents Are Only As Good As The RNA Knowledge Behind Them 9/3/2026

    The RNA field is producing extraordinary volumes of information. Yet, giving an AI system access to more information does not necessarily make the system more scientifically intelligent.

  2. Soliman Says… 5 Questions Every RNA Platform Must Answer Before Investors Write The Check 7/21/2026

    A practical framework for evaluating whether an RNA company has the science, strategy, scalability, and discipline to become a lasting platform.

  3. The Hidden Bottleneck In Advanced Therapies Isn't Science… It's Translational Friction 6/26/2026

    Scientific breakthroughs may spark innovation, but operational excellence ultimately determines which advanced therapies reach patients.

  4. What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing 5/28/2026

    RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.

  5. Oligos, mRNA, Or Gene Editing: Where Should You Bet? 4/13/2026

    Investing in RNA and gene editing requires balancing risk, timing, and scale — understanding how oligos, mRNA, and CRISPR each drive value across a converging biotech landscape.

  6. How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation 3/19/2026

    Subtle FDA signals — especially in pre-IND talks — are quietly shaping RNA investment. Early regulatory feedback on CMC and comparability now drives how investors assess risk and allocate capital.

  7. 2026 RNA Investment Landscape: Recent Deals, IPOs, And Venture Trends 2/22/2026

    As RNA investing matures, capital is flowing toward delivery, durability, and regulatory credibility. This column breaks down the deals, IPO signals, and venture theses shaping RNA’s 2026 winners—and why.

  8. Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes Next 1/9/2026

    Oligonucleotide therapies have proven clinical value, but scaling beyond rare disease remains hard. William Soliman, Ph.D., BCMAS, breaks down the manufacturing, delivery, and CMC realities shaping what comes next.